<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336035">
  <stage>Registered</stage>
  <submitdate>28/09/2010</submitdate>
  <approvaldate>1/10/2010</approvaldate>
  <actrnumber>ACTRN12610000824066</actrnumber>
  <trial_identification>
    <studytitle>The effectiveness of Autologous Blood Injections for the treatment of mid portion Achilles tendinopathy- a double blind randomised control trial.</studytitle>
    <scientifictitle>The medium term effectiveness of autologous blood injections as an additional treatment to an eccentric strengthening programme for mid portion Achilles tendinopathy using the Victorian Institute of Sport Assessment- Achilles (VISA-A) scale- a double blind randomised control trial.</scientifictitle>
    <utrn>U1111-1117-2641</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Achilles Tendinopathy</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Autologous Blood Injection. 3ml of blood will be drawn from either antecubital fossa with sterile no touch technique. No local anasthetic will be used. The blood will then be injected with a sterile no touch technique around the area of maximal Achilles tendon tenderness. It will not be injected directly into the tendon. There will not be dry needling and it will not be done under ultrasound guidance. We would hope that the time between aspiration and reinjection to be under one minute. All participants will have one injection, carried out two times in total, a month apart. All participants will carry out the standard Alfredson's eccentric exercise regime.</interventions>
    <comparator>Sham injection. This group will also have 3ml of blood taken from their antecubital fossa. They will have an injection around the area of maximal Achilles tendon tenderness. The same needling technique (three passes of the needle) will be used. No substance will be injected. All participants will carry out the standard Alfredson's eccentric exercise regime.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>VISA-A score</outcome>
      <timepoint>A VISA-A score will be done at randomisation (baseline) and again at 1,2,3,&amp; 6 months subsequent to this.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Likert score to assess overall improvement
Ability to return to tendon loading sport </outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria: patients presenting to sports medicine/physiotherapy/ general practice clinics with first presentation of mid portion Achilles tendinopathy of at least 3 months duration</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria: Bilateral Achilles tendinopathy, significant coagulopathy predisposing to bleeding, previous adjuvant treatment of the Achilles tendinopathy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Participants will be initially assessed regards their eligibility for the study. If they meet the inclusion/ exclusion criteria and have a diagnosis of Achilles Tendinopathy, they will be randomly allocated to either the treatment or placebo group by way of a computer generated randomisation code. Neither the examining doctor nor patient will know their group allocation. Allocation to either group will be concealed to both the participant and the examiner who determines eligibility for inclusion into the trial.</concealment>
    <sequence>Randomisation was by shuffled and sealed envelopes.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>25/09/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>52</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor Ngaire Kerse</primarysponsorname>
    <primarysponsoraddress>Department of General Practice
Tamaki Campus
The University of Auckland
Private Bag 92019
Auckland 1142</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Dr Kevin Bell</fundingname>
      <fundingaddress>305/8 Shoreline Drive, Rhodes, Sydney, NSW 2138</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other</sponsortype>
      <sponsorname>Wakefield Sportsmed</sponsorname>
      <sponsoraddress>Rintoul St
Newtown
Wellington
6021</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of the study is to determine whether the addition of an autologous blood injection as an adjuvant therapy provides added benefit on top of the standard Alfredson's eccentric exercise regime alone for those with mid portion Achilles tendinopathy.</summary>
    <trialwebsite />
    <publication>Published in the British Medical Journal on 18/4/13
BMJ2013;346:f2310</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Central Ethics Committee</ethicname>
      <ethicaddress>PO Box 5013
Wellington
6011</ethicaddress>
      <ethicapprovaldate>21/09/2010</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr Kevin Bell</name>
      <address>Sydney Sports Medicine Centre, 6 Figtree Drive, Sydney Olympic Park, NSW 2127</address>
      <phone>+61 2 9764 3131</phone>
      <fax>+61 2 9764 3443</fax>
      <email>kevtherev77@hotmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Kevin Bell</name>
      <address>Sydney Sports Medicine Centre, 6 Figtree Drive, Sydney Olympic Park, NSW 2127</address>
      <phone>+61 2 9764 3131</phone>
      <fax>+61 2 9764 3443</fax>
      <email>kevtherev77@hotmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Kevin Bell</name>
      <address>Sydney Sports Medicine Centre, 6 Figtree Drive, Sydney Olympic Park, NSW 2127</address>
      <phone>+61 2 9764 3131</phone>
      <fax>+61 2 9764 3443</fax>
      <email>kevtherev77@hotmail.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Kevin James Bell</name>
      <address>Sydney Sports Medicine Centre, 6 Figtree Drive, Sydney Olympic Park, NSW 2127</address>
      <phone>+61 478588889</phone>
      <fax>+61 2 9764 3443</fax>
      <email>kevtherev77@hotmail.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>